See more : NSTAR Electric Company PFD 4.25% (NSARP) Income Statement Analysis – Financial Results
Complete financial analysis of Sage Therapeutics, Inc. (SAGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sage Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- InsuraGuest Technologies Inc. (ISGIF) Income Statement Analysis – Financial Results
- Public Joint Stock Company Rosinter Restaurants Holding (ROST.ME) Income Statement Analysis – Financial Results
- McLaren Resources Inc. (MCL.CN) Income Statement Analysis – Financial Results
- Sansha Electric Manufacturing Co.,Ltd. (6882.T) Income Statement Analysis – Financial Results
- Unicharm Corporation (8113.T) Income Statement Analysis – Financial Results
Sage Therapeutics, Inc. (SAGE)
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.46M | 7.69M | 6.31M | 1.11B | 6.87M | 90.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.16M | 813.00K | 553.00K | 565.00K | 400.00K | 1.10M | 500.00K | 281.00K | 115.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 84.30M | 6.87M | 5.76M | 1.11B | 6.47M | 89.17M | -500.00K | -281.00K | -115.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 97.50% | 89.42% | 91.23% | 99.95% | 94.18% | 98.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 356.24M | 326.16M | 283.17M | 292.71M | 368.82M | 282.11M | 210.28M | 120.76M | 69.36M | 24.10M | 14.36M | 7.23M |
| General & Administrative | 274.52M | 227.70M | 183.50M | 196.95M | 345.78M | 201.40M | 62.88M | 39.41M | 25.29M | 9.71M | 3.38M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.60M | 11.18M | 5.27M | 3.08M | 0.00 | 0.00 | 0.00 |
| SG&A | 274.52M | 227.70M | 183.50M | 196.95M | 345.78M | 201.40M | 62.88M | 39.41M | 25.29M | 9.71M | 3.38M | 2.40M |
| Other Expenses | 33.39M | 15.00K | 134.00K | 250.00K | 82.00K | 22.00K | -64.00K | -35.00K | -23.00K | -9.00K | -3.00K | -1.00K |
| Operating Expenses | 664.15M | 553.86M | 466.66M | 489.67M | 714.59M | 483.51M | 273.16M | 160.16M | 94.65M | 33.81M | 18.28M | 9.63M |
| Cost & Expenses | 666.30M | 554.68M | 467.22M | 490.23M | 714.99M | 483.51M | 273.16M | 160.16M | 94.65M | 33.81M | 18.28M | 9.63M |
| Interest Income | 38.74M | 14.19M | 2.88M | 9.60M | 27.80M | 20.33M | 3.10M | 1.21M | 178.00K | 8.00K | 1.00K | 0.00 |
| Interest Expense | 0.00 | 14.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.39M | 1.12M | 4.18M | 2.63M | 2.28M | 1.10M | 500.00K | 281.00K | 115.00K | 51.00K | 47.00K | 44.00K |
| EBITDA | -545.07M | -545.87M | -456.73M | 626.60M | -705.84M | -392.10M | -269.62M | -160.16M | -94.65M | -33.81M | -18.23M | -9.59M |
| EBITDA Ratio | -630.47% | -7,116.69% | -7,306.74% | 58.49% | -10,310.48% | -435.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -579.85M | -546.99M | -460.91M | 596.23M | -708.12M | -393.24M | -273.16M | -160.16M | -94.65M | -33.81M | -18.28M | -9.63M |
| Operating Income Ratio | -670.69% | -7,116.69% | -7,306.74% | 53.51% | -10,310.48% | -435.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 38.36M | 14.21M | 3.02M | 9.85M | 27.89M | 20.36M | 3.04M | 1.18M | 155.00K | -1.00K | -2.00K | -1.00K |
| Income Before Tax | -541.49M | -532.78M | -457.89M | 606.07M | -680.24M | -372.88M | -270.12M | -158.99M | -94.50M | -33.81M | -18.28M | -9.63M |
| Income Before Tax Ratio | -626.32% | -6,931.88% | -7,258.91% | 54.40% | -9,904.46% | -413.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -29.52M | -7.07M | 15.52M | -30.09M | 20.36M | -3.63M | -1.49M | -293.00K | -59.00K | 2.00K | 0.00 |
| Net Income | -541.49M | -503.27M | -450.83M | 606.07M | -650.15M | -372.88M | -270.12M | -158.99M | -94.50M | -33.81M | -18.28M | -9.63M |
| Net Income Ratio | -626.32% | -6,547.84% | -7,146.91% | 54.40% | -9,466.38% | -413.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.05 | -8.49 | -7.68 | 11.66 | -12.79 | -8.08 | -7.09 | -4.75 | -3.40 | -1.57 | -1.09 | -0.57 |
| EPS Diluted | -9.05 | -8.49 | -7.68 | 11.43 | -12.79 | -8.08 | -7.09 | -4.75 | -3.40 | -1.57 | -0.73 | -0.39 |
| Weighted Avg Shares Out | 59.84M | 59.31M | 58.67M | 51.98M | 50.83M | 46.12M | 38.10M | 33.47M | 27.78M | 21.57M | 16.77M | 16.77M |
| Weighted Avg Shares Out (Dil) | 59.84M | 59.31M | 58.67M | 53.00M | 50.83M | 46.12M | 38.11M | 33.49M | 27.78M | 21.57M | 24.96M | 24.96M |
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Sage Therapeutics to end Huntington's disease trial after key therapy fails again
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE
Source: https://incomestatements.info
Category: Stock Reports